Estimation of Outcome and Quality of Life in ECMO Patients (ESTRELLA)

ESTimation of Outcome by Health-Care PRoviders Compared With TruE Outcome in Patients Undergoing Veno-arteriaL and Veno-venous ExtracorporeaL MembrAne Oxygenation

The availability as well as the use of extracorporeal membrane oxygenation (ECMO) systems for severe acute respiratory or cardiocirculatory failure is steadily increasing. The decision to initiate ECMO therapy is predominantly made in emergency situations, for which the focus is on acute survival. The decisions if a patient will profit from ECMO therapy are mainly made from clinical experience and educated guess by the attending team. However, it is unknown how useful these clinical predictions are. Therefore, this observational study will compare estimated and real outcome of ECMO patients.

Study Overview

• Status: Recruiting
• Conditions: Extracorporeal Membrane Oxygenation
• Intervention / Treatment: Other: estimation of patient outcome by health care providers

Detailed Description

The availability as well as the use of extracorporeal membrane oxygenation (ECMO) systems for severe acute respiratory (veno-venous, vv-ECMO) or cardiocirculatory (veno-arterial, va-ECMO) failure is steadily increasing. Despite increasing experience of specialized centres, mortality of ECMO patients remains high and only about 50% survive the initial hospital stay. For those patients who do leave the hospital alive, quality of life after this invasive therapy with long stays in the intensive care unit (ICU) is often limited and participation in social life can be difficult. Quality of life and the life-impact after ECMO therapy is, in contrast to hard endpoints such as mortality, insufficiently studied and currently only scarce data exist from large prospective cohort studies. Further, predictive scores and associated risk factors for patient-centred outcomes are not available.

The decision to initiate ECMO therapy is predominantly made in emergency situations, for which the focus is on acute survival. As such, the long-term implications in terms of quality of life and life-impact of ECMO treatment enjoy only limited consideration at an early time point. Further, the existing scores for prediction in ECMO were developed for mortality and reliable data on long-term life-impact are scarce. Therefore, while these decisions are influenced by empirical factors like patient-age, point-of-care laboratory parameters (e.g. lactate) or the neurological status of the patient, the clinical experience and educated guess in terms of prognosis and potential treatment futility by the attending team remains a crucial factor. This applies not only to ECMO initiation but also to decisions on continuation and termination. This approach to decision-making may be problematic since it has been shown for other settings that clinicians tend to overestimate the success of an intervention. Currently, there are no data evaluating in how far this also applies to ECMO therapy and if indeed, there is a mismatch between estimated and observed outcomes in ECMO patients. Considering the crucial role of subjective prognosis estimates, it becomes of major interest to quantify the potential mis-calibration between clinicians estimated and observed outcomes. Further, factors like Outcome uncertainties, potential doubts regarding treatment utility vs futility, and the immediate finality of these demanding decisions expose ICU health-care personnel to a relevant psychological burden. As shown by Johnson-Coyle and colleagues, both moral distress and burnout have a negative impact on job satisfaction. Moral distress occurs when one believes to know what is ethically right but something or someone limits their ability to do the right thing. Preliminary studies have shown a high incidence of moral distress in the care of patients with mechanical circulatory support systems, with particularly pronounced stress among nursing personnel. If these factors have significant impact on professional judgement is not clear in this context.

In a small single centre pilot study, we prospectively recruited 50 va-ECMO patients at the University Hospital Duesseldorf from March until November 2023 and investigated if ECMO care providers could predict in-hospital mortality in these patients. For these 50 patients we obtained 135 completed questionnaires within 24 hours and 111 answered questionnaires at day 4 to7 after initiation of ECMO therapy from consultants, residents and nursing personnel. Out of 50 patients 21 patients (42%) died during the initial hospital stay. Overall sensitivity and specificity of estimates were 57.9% and 85.9% respectively at 24 hours after start of ECMO therapy (precision: 75%, accuracy: 74.1%, F1 score: 65.3%). In a subgroup analysis, consultants showed highest agreement of estimated and actual in hospital mortality, whereas residents showed lowest agreement (see table below). At day 4 to 7 overall predictions had lower sensitivity, accuracy, precision and F1-score as compared to estimates on day 1 after ECMO initiation, however specificity slightly increased (sens: 35% spec: 91.5% acc: 71.1% F1-score: 46.7% precision: 70%). Highest values for sensitivity, accuracy and F1-score, were reached in subgroup of nursing personnel (see table below). Notably, years of experience in critical care were higher in consultants and nursing personnel as compared to residents (consultants: 10.8 ± 6.7 years versus residents: 1.4 ± 1.5 years versus nursing personnel: 15.8 ± 10.4 years).

Based on the results of our pilot data, we hypothesize that:

1. Subjective prognosis estimates by health care providers underestimate (low sensitivity) actual mortality. We expect that this will also account for reduced functionality and quality of life.
2. Estimations will vary significantly between different groups of health care professionals and levels of experience in critical care as well as between different time points of assessment. Specifically we expect, that prediction accuracy will improve with higher years of experience in critical care and that predictions for mortality will be more accurate immediately after ECMO initiation as compared to later study time points. This might be influenced by the fact that a substantial number of patients with poor prognosis will die within the first four days of ECMO therapy. Hence, estimation of outcome in the remaining patients is more difficult.
3. Agreement between estimated and observed outcomes will differ significantly between centres with different levels of experience (high-volume versus low-volume centres). Expecting higher accuracy of outcome estimates in high-volume centres with higher experience as compared to low-volume centres.
4. Additionally, we expect that high levels of moral distress influence professional judgement leading to negative estimated prognosis and low precisions of estimations.

Therefore, we aim to conduct the ESTRELLA study as large nationwide multicentre prospective cohort study to dissect usability of clinical estimates for outcome prediction in ECMO patients and to identify suitable factors for prediction of poor functional health in these patients.

• Study Type: Observational
• Enrollment (Estimated): 1000

Contacts and Locations

• Study Contact: Name: René M'Pembele, MD; Phone Number: 02118118451; Email: rene.mpembele@med.uni-duesseldorf.de
• Study Contact Backup: Name: Sebastian Roth, MD; Phone Number: 02118118451; Email: sebastian.roth@med.uni-duesseldorf.de

Study Locations

• Germany
  • NRW
    • Duesseldorf, NRW, Germany, 40225
      • Recruiting
      • University Hospital Duesseldorf
      • Contact: René M'Pembele, MD; Phone Number: +4902118118451; Email: Rene.MPembele@med.uni-duesseldorf.de

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

All patients aged above 18 years in the ICU with a vv- or va-ECMO for less than 24 hours will be included.

Description

Inclusion Criteria:

• age ≥ 18 years
• start of ECMO therapy ≤24h
• written informed consent from patient or health-care proxy

Exclusion Criteria:

• age < 18 years
• Language barrier (communication in German/local language or English not possible).
• no ECMO therapy or ECMO therapy longer than 24h
• no written consent

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

ECMO patients; Patients recieving Venoarterial or Venovenous extracorporeal membrane oxygenation (VA-ECMO, VV-ECMO)

Other: estimation of patient outcome by health care providers; On day 1 after study inclusion as well as day 4-7, the responsible health-care providers (at least one nurse, one resident and one consultant with the board certification intensive care medicine) will estimate the patient's expected functional outcome at 6 and 12 months after the start of ECMO therapy. Health-care providers responsible for the patient at that time will be surveyed (multiple questionnaires to detect specific differences within one person are not planned). For the purpose of functional outcome estimation, the modified Rankin scale (mRS) is used.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Agreement between estimated outcome by healthcare providers and actual patient outcome on Modified Rankin scale mRS	The primary endpoint of this study will be the agreement between functional performance of patients estimated by different healthcare provider groups and actual functional performance of patients after start of ECMO therapy measured by the 7-item mRS.	6 months and 12 months after ECMO therapy

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Disability-free survival (WHODAS 2.0)	As secondary endpoints we will assess disability free survival at 6 and 12 months after ECMO therapy using the WHODAS 2.0 questionnaire with a disability threshold of ≥16 % for mild disability and ≥35% for severe disability as described previously by Shulman et al.	6 months and 12 months after ECMO therapy
Days alive and out of hospital (DAOH)	we will assess Days alive and out of hospital at 6 and 12 months after initiation of ECMO therapy, as additional life impact parameter which was previously investigated in other cohorts	6 months and 12 months after ECMO therapy
Moral distress	we will assess the level of moral distress of ICU health care providers (consultants, residents and nursing personnel) taking care of the individual patient using the Moral Distress Thermometer.	Day 1 and day 4-7 of ECMO therapy

Collaborators and Investigators

• Sponsor: Heinrich-Heine University, Duesseldorf
• Investigators: Principal Investigator: René M'Pembele, MD, Heinrich-Heine University, Duesseldorf; Principal Investigator: Sebastian Roth, MD, Heinrich-Heine University, Duesseldorf

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2024
• Primary Completion (Estimated): January 1, 2028
• Study Completion (Estimated): January 1, 2029

Study Registration Dates

• First Submitted: May 2, 2024
• First Submitted That Met QC Criteria: May 2, 2024
• First Posted (Actual): May 6, 2024

Study Record Updates

• Last Update Posted (Actual): May 6, 2024
• Last Update Submitted That Met QC Criteria: May 2, 2024
• Last Verified: May 1, 2024

More Information

Terms related to this study

• Keywords: ECMO; health related quality of life; Outcome estimation
• Other Study ID Numbers: 2024-RM-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: There is no plan to share IPD.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No